In order to validate some of the observations reported above in the MIBC TCGA dataset of cystectomy specimens, we explored the independent data from the publically available IMvigor 210 study [15], a dataset with 348 metastatic urothelial bladder cancer patients, mostly resistant to previous cisplatin based chemotherapy (78.2%), and all treated with atezolizumab, a PD-L1 inhibitor. The gene discussed is CD274; the disease is bladder transitional cell carcinoma.